Trial Profile

A Phase II, Multicentre Booster Study to Evaluate Booster Vaccination With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or to Evaluate the Immune Memory Following the Administration of a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children, Previously Vaccinated in Infancy in the Primary Study 11PN-PD-DIT-002 (103488)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 11-valent vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
Indications Pneumococcal infections
Focus Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

13 Apr 2012 Planned patient number for the booster trial (EudraCT2008-002345-23) is now 689.
13 Apr 2012 Status of the booster trial (NCT00307567) is completed.
13 Apr 2012 Actual initiation date for the booster trial (NCT00307567) is now Nov 2005.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com